Amgen, Inc. (AMGN)
467.06
-1.05
(-0.22%)
USD |
NASDAQ |
Nov 12, 16:00
469.13
+2.07
(+0.44%)
After-Hours: 04:46
Amgen Enterprise Value : 293.45B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 293.45B |
| November 11, 2026 | 294.02B |
| November 10, 2026 | 292.46B |
| November 09, 2026 | 292.46B |
| November 06, 2026 | 289.86B |
| November 05, 2026 | 289.78B |
| November 04, 2026 | 299.63B |
| November 03, 2026 | 290.31B |
| November 02, 2026 | 292.58B |
| October 30, 2026 | 292.88B |
| October 29, 2026 | 290.03B |
| October 28, 2026 | 285.21B |
| October 27, 2026 | 283.11B |
| October 26, 2026 | 281.32B |
| October 23, 2026 | 278.41B |
| October 22, 2026 | 282.75B |
| October 21, 2026 | 277.92B |
| October 20, 2026 | 278.24B |
| October 19, 2026 | 270.67B |
| October 16, 2026 | 274.75B |
| October 15, 2026 | 275.58B |
| October 14, 2026 | 271.30B |
| October 13, 2026 | 264.12B |
| October 12, 2026 | 266.68B |
| October 09, 2026 | 265.22B |
| Date | Value |
|---|---|
| October 08, 2026 | 261.20B |
| October 07, 2026 | 264.25B |
| October 06, 2026 | 258.58B |
| October 05, 2026 | 258.79B |
| October 02, 2026 | 258.82B |
| October 01, 2026 | 261.11B |
| September 30, 2026 | 268.81B |
| September 29, 2026 | 272.33B |
| September 28, 2026 | 269.36B |
| September 25, 2026 | 267.45B |
| September 24, 2026 | 262.82B |
| September 23, 2026 | 262.85B |
| September 22, 2026 | 265.09B |
| September 21, 2026 | 255.86B |
| September 18, 2026 | 251.80B |
| September 17, 2026 | 248.62B |
| September 16, 2026 | 246.77B |
| September 15, 2026 | 246.39B |
| September 14, 2026 | 249.55B |
| September 11, 2026 | 247.31B |
| September 10, 2026 | 250.08B |
| September 09, 2026 | 254.84B |
| September 08, 2026 | 255.86B |
| September 04, 2026 | 279.68B |
| September 03, 2026 | 283.41B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 226.62B |
| Regeneron Pharmaceuticals, Inc. | 91.75B |
| AbbVie, Inc. | 590.62B |
| Biogen, Inc. | 43.52B |
| Vertex Pharmaceuticals, Inc. | 137.73B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.864B |
| Revenue (Quarterly) | 10.36B |
| Total Expenses (Quarterly) | 6.497B |
| EPS Diluted (Quarterly) | 7.077 |
| Gross Profit Margin (Quarterly) | 73.09% |
| Profit Margin (Quarterly) | 37.29% |
| Earnings Yield | 3.69% |
| Operating Earnings Yield | 5.46% |
| Normalized Earnings Yield | 4.022 |